
Arrowhead Pharmaceuticals, Inc. (Nasdaq ARWR) is a commercial stage biopharmaceutical company that develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of our RNAi technologies enables us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics. Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.
Arrowhead’s corporate headquarters is in Pasadena, CA with research and development teams in Madison, WI & San Diego, CA, and a state of the art manufacturing facility in Verona, WI. Our employees are nimble, science-driven innovators who are collaborating to bring new therapies to patients in need.
The Position
Let's do something amazing together! The Associate Director, National Accounts will play a critical role in enabling patient access to Arrowhead's first commercial asset, Redemplo (plozasiran, siRNA targeting APOC3), as well as an expanding pipeline of innovative therapies across multiple therapeutic areas. This product has demonstrated compelling clinical data to date and received approval in November 2025 for the treatment of Familial Chylomicronemia Syndrome (FCS). Redemplo (plozasiran) remains in late-stage development for the treatment of Severe Hypertriglyceridemia (SHTG), with approval anticipated in Q2 2027.
This individual will own a dedicated portfolio of payer and PBM accounts while also serving as a strategic, customer-facing partner to the National Account Directors (NADs) on Arrowhead's broader national accounts, and as a centralized source of truth for payer contracts, formulary coverage, payer policies, and utilization management criteria across Arrowhead's U.S. Market Access footprint. The role will translate formulary, claims, and specialty pharmacy data into payer strategy and field-facing insights, partnering closely with the NADs, Trade, Distribution, and Patient Services leadership to strengthen Arrowhead's payer intelligence capabilities and represent that intelligence directly to internal leadership and external payer and PBM audiences. This is an individual contributor role with no direct reports, requiring high executive presence, polished presentation skills, and the confidence to stand alongside the NADs in front of senior payer and PBM stakeholders.
This is a field-based or remote role that requires periodic travel to Arrowhead's Corporate Headquarters in Pasadena, CA, and to payer and PBM industry conferences, as business needs dictate
Responsibilities
Requirements
Preferred
Arrowhead provides competitive salaries and an excellent benefit package.
Candidates must have current, valid authorization to work in the country where this role is located.

At Arrowhead Pharmaceuticals we are breaking the mold of medicine. We are pushing the boundaries of therapeutic development and revolutionizing how we care for hard-to-treat illnesses.
As a company we harness collaboration and innovation to rapidly advance drugs from discovery to the clinic.
All applicants: Please be aware of employment scams using Arrowhead’s name and the names of Arrowhead’s employees. All job related Arrowhead communication should come from the domain @arrowheadpharma.com.